Filtered By:
Drug: Avandia
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 42 results found since Jan 2013.
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Conclusions Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways.
Abstract
PPARγ-achieved neuroprotection in experimental stroke has been explained by the inhibition of inflammatory genes, an action in which 5-LO, Alox5, is involved. In addition, PPARγ is known to promote the expression of CD36, a scavenger receptor that binds lipoproteins and mediates bacterial recognition and also phagocytosis. As phagocytic clearance of neutrophils is a requisite for resolution of the inflammatory response, PPARγ-induced CD36 expression might help to limit inflammatory tissue injury in stroke, an effect in which 5-LO might also be involved. Homogenates, sections, and cellular suspensions w...
Source: Journal of Leukocyte Biology - December 12, 2013 Category: Hematology Authors: Ballesteros I, Cuartero MI, Pradillo JM, de la Parra J, Pérez-Ruiz A, Corbí A, Ricote M, Hamilton JA, Sobrado M, Vivancos J, Nombela F, Lizasoain I, Moro MA Tags: J Leukoc Biol Source Type: research
N2 Neutrophils, Novel Players in Brain Inflammation After Stroke: Modulation by the PPAR{gamma} Agonist Rosiglitazone Basic Sciences
Conclusions—
We present the first evidence of neutrophil reprogramming toward an N2 phenotype in brain inflammation, which can be modulated by activation of the peroxisome proliferator-activated receptor- nuclear receptor. We also show that N2 polarization is associated with an increased neutrophil clearance, thus suggesting that this switch is a crucial event for resolution of inflammation that may participate in neuroprotection.
Source: Stroke - November 25, 2013 Category: Neurology Authors: Cuartero, M. I., Ballesteros, I., Moraga, A., Nombela, F., Vivancos, J., Hamilton, J. A., Corbi, A. L., Lizasoain, I., Moro, M. A. Tags: Basic Sciences Source Type: research
{Delta}9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPAR{gamma} DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE
Conclusions
Even though 9–THC and pioglitazone are both protective against MPP+ only 9–THC induces PPAR dependent mitochondrial biogenesis, a mechanism that may be beneficial for the treatment of PD.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Zeissler, M.-L., Eastwood, J., Oliver Hanemann, C., Zajicek, J., Carroll, C. Tags: Immunology (including allergy), Drugs: CNS (not psychiatric), Parkinson's disease, Stroke Association of British Neurologists (ABN) joint meeting with the Royal College of Physicians (RCP), London, 23-24 October 2013 Source Type: research
Fatal heat stroke associated with topiramate therapy
A 40-year-old man with diabetes and seizure disorder was found at home unresponsive and “very hot to touch” by his father 40 minutes before emergency medical services arrival. His usual medications included topiramate, divalproex sodium, and rosiglitazone/metformin. Paramedics administered oxygen, intravenous fluids, and naloxone. They did not witness or report seizure activity. Upon emergency department arrival, the patient was unresponsive (Glasgow Coma Scale 3), hypotensive (94/50 mm Hg), and tachypneic (32 breaths per minute), with a heart rate of 60 beats per minute and elevated rectal temperature peaking at 43.2...
Source: The American Journal of Emergency Medicine - September 3, 2013 Category: Emergency Medicine Authors: Stephen W Borron, Robert Woolard, Susan Watts Tags: Case Reports Source Type: research
Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
CONCLUSIONS: Among patients with type 2 diabetes and CAD in the BARI 2D trial, neither on-treatment nor propensity matched analysis supported an association of rosiglitazone treatment with an increase in major ischemic cardiovascular events.
CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Identifier: NCT00006305.
PMID: 23857320 [PubMed - as supplied by publisher]
Source: Circulation - July 15, 2013 Category: Cardiology Authors: Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber AJ, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL, for the BARI 2D Investigators Tags: Circulation Source Type: research
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
Conclusions: Comprehensive procedures were used for rigorous event reascertainment and readjudication in a previously completed open-label, global clinical trial. These procedures used in this unique situation were consistent with other common approaches in the field, were enhanced to address the FDA concerns about the original RECORD trial results, and could be considered by clinical trialists designing event readjudication protocols for drug development programs that have been completed.
Source: American Heart Journal - June 24, 2013 Category: Cardiology Authors: Renato D. Lopes, Sheila Dickerson, Gail Hafley, Shana Burns, Sandra Tourt-Uhlig, Jennifer White, L. Kristin Newby, Michel Komajda, John McMurray, Robert Bigelow, Philip D. Home, Kenneth W. Mahaffey Tags: Trial Design Source Type: research
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Conclusions: Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.
Source: American Heart Journal - June 6, 2013 Category: Cardiology Authors: Kenneth W. Mahaffey, Gail Hafley, Sheila Dickerson, Shana Burns, Sandra Tourt-Uhlig, Jennifer White, L. Kristin Newby, Michel Komajda, John McMurray, Robert Bigelow, Philip D. Home, Renato D. Lopes Tags: Diabetes and Metabolism Source Type: research
Certain statins can raise risk of developing diabetes
Overall benefits of statins outweigh risks, say expertsRelated items from OnMedicaRegulators suspend Avandia over safety concernsIgnored cholesterol blamed for heart attacksPolypill could halve cardiovascular events Hospitals fail women with myocardial infarctionStatins halve heart attack and stroke risk in healthy adults
Source: OnMedica Latest News - May 24, 2013 Category: UK Health Source Type: news
A Non-Epileptiform Event in the Course of rTMS: A Case for Close Physician Monitoring
We present the following case to demonstrate the importance of having physician supervision of patients undergoing repetitive transcranial magnetic stimulation (rTMS) treatments. The patient was a married 60-year-old male with a diagnosis of Major Depressive Disorder and Generalized Anxiety Disorder who had continuous symptoms of depression since the early 1980s despite receiving at least 7 adequate antidepressant treatments. The patient had several comorbid medical conditions. The patient did not have any previous history of seizure, stroke, an abnormal EEG, head injury, neurosurgical procedure, implanted devices, frequen...
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - April 29, 2013 Category: Neurology Authors: F. Andrew Kozel, Paul E. Croarkin, Kimberly S. Mapes Tags: Letters to the Editor Source Type: research
Smurf2‐mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke
Abstract
EZH2 plays an important role in stem cell renewal and maintenance by inducing gene silencing via its histone methyltransferase activity. Previously, we showed that EZH2 downregulation enhances neuron differentiation of human mesenchymal stem cells (hMSCs); however, the underlying mechanisms of EZH2‐regulated neuron differentiation are still unclear. Here, we identify Smurf2 as the E3 ubiquitin ligase responsible for the polyubiquitination and proteasome‐mediated degradation of EZH2, which is required for neuron differentiation. A ChIP‐on‐chip screen combined with gene microarray analysis revealed that PPAR...
Source: EMBO Molecular Medicine - March 25, 2013 Category: Molecular Biology Authors: Yung‐Luen Yu, Ruey‐Hwang Chou, Woei‐Cherng Shyu, Shu‐Ching Hsieh, Chen‐Shiou Wu, Shu‐Ya Chiang, Wei‐Jung Chang, Jia‐Ni Chen, Yen‐Ju Tseng, Yu‐Hsuan Lin, Wei Lee, Su‐Peng Yeh, Jennifer L. Hsu, Cheng‐Chieh Yang, Shih‐Chieh Hung, Mi Tags: Research Article Source Type: research
Families face battle with GSK over dangerous diabetes drug
Exclusive: Pharmaceutical giant resists claims despite settlement with victims in USThousands of families in the UK could be deprived of compensation for the death or harm of a relative caused by the diabetes drug Avandia, even though the British maker has agreed to pay billions of dollars to settle similar claims in the US.The licence for Avandia was revoked in Europe, in September 2010, because of evidence that it could cause heart failure and heart attacks. The drug can still be prescribed in the US, but not to patients at risk of heart problems.A scientist with the Food and Drug Administration estimated that Avandia co...
Source: Guardian Unlimited Science - January 29, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian United States World news Pharmaceuticals industry Medical research Legal aid Law UK news Diabetes GlaxoSmithKline Business Source Type: news
